#Taipei #United States #Immuno-Oncology #HanchorBio #HCB101

HanchorBio Secures US Patent for HCB101: A Breakthrough in Cancer Treatment

HanchorBio, a biotech company based in Taipei, Shanghai, and San Francisco, has announced a significant milestone in its efforts to combat cancer. The company has been granted a US patent for its innovative fusion protein, HCB101, which targets the SIRPα/CD47 pathway—an essential mechanism in tumor immune evasion. This achievement could transform the landscape of immuno-oncology, the branch of medicine focused on harnessing the immune system to fight cancer.

Understanding HCB101 and Its Mechanism of Action

HCB101 is developed through HanchorBio's proprietary FBDB™ (Fc-Based Designed Biologics) platform. This engineered fusion protein is meticulously designed to enhance the immune system's capacity to identify and eliminate cancer cells. By preventing tumors from evading immune detection, HCB101 aims to reactivate the body's macrophages, a type of white blood cell that plays a crucial role in destroying cancer cells.

The innovation behind HCB101 lies in its unique structure—engineered with specific amino acid substitutions at undisclosed sites on SIRPα. This strategic mutation significantly boosts the protein's affinity for CD47, a marker frequently exploited by cancer cells to escape immune responses. The USPTO highlighted these unique features as a testament to HCB101's novelty and potential effectiveness compared to existing therapies.

The Significance of the Patent Grant

The US patent (Patent No. 12,447,195) awarded to HanchorBio represents not just a legal victory; it positions the company as a leader in the biopharmaceutical industry. This patent enhances HanchorBio's competitive edge, facilitating negotiations for licensing and potential partnerships that can accelerate the development and distribution of HCB101.

Dr. Scott Liu, the chairman of HanchorBio, emphasized the importance of this patent in showcasing Taiwan's biotechnology sector's innovative capabilities. He stated, "The US patent grant for HCB101 is a testament to HanchorBio's robust R&D capabilities in immunotherapy, while also illustrating the heights of innovation that Taiwan's biotech industry is capable of reaching."

Strategic Importance of the US Market

Selecting the US for the initial patent filing was a calculated move by HanchorBio. As the world's leading market for biopharmaceutical innovation, US patent approval not only validates the company's innovations but also serves as a benchmark for similar filings in other jurisdictions. Such recognition can propel the company’s reputation, facilitating smoother examinations in regions like Europe and Asia.

HanchorBio collaborated with Fish & Richardson, a prominent intellectual property law firm, to navigate this intricate patent process. Their guidance was instrumental in achieving this pivotal milestone, which sets the stage for HanchorBio's future expansions across global markets.

The Future of HanchorBio's Global Patent Strategy

Following this patent, HanchorBio plans to pursue patent filings in Europe, Taiwan, and several other Asian nations. This global strategy aims to solidify its position in immuno-oncology and bolster the company's standing in international licensing deals and collaborations.

The grant of the HCB101 patent marks a critical step for HanchorBio as it seeks to expand its influence and markets worldwide, demonstrating a commitment to address unmet medical needs in oncology.

About HanchorBio

Founded by experienced veterans in the pharmaceutical industry, HanchorBio is devoted to reimagining cancer therapies through cutting-edge immuno-oncology solutions. Utilizing its proprietary FBDB™ platform, the company is paving the way for next-generation biologics tailored to overcome the challenges faced by current therapies focusing on PD-1 and PD-L1. For more information about HanchorBio and its innovative approaches to cancer treatment, visit HanchorBio’s official website.